Enoximone: Difference between revisions

Enoximone
Clinical data
Routes of; administration	Intravenous
ATC code	C01CE03 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only) ;
Pharmacokinetic data
Bioavailability	50% (oral)
Protein binding	85%
Metabolism	Hepatic oxidation
Elimination half-life	4 to 10 hours
Excretion	Renal (60 to 70%)
Identifiers
	IUPAC name 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-; dihydroimidazol-2-one;
CAS Number	77671-31-9;
PubChem CID	53708;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C12H12N2O2S
Molar mass	248.302 g/mol
3D model (JSmol)	Interactive image;
	SMILES CSc1ccc(cc1)C(=O)C2=C(C)NC(=O)N2;

Revision as of 02:16, 9 August 2012

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.

@@ Line 27: / Line 27: @@
 {{CMG}}
-{{Editor Join}}
 ==Overview==

Clinical data

Routes of administration	Intravenous
ATC code	C01CE03 (WHO)
Legal status
Legal status	UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	50% (oral)
Protein binding	85%
Metabolism	Hepatic oxidation
Elimination half-life	4 to 10 hours
Excretion	Renal (60 to 70%)
Identifiers
IUPAC name 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3- dihydroimidazol-2-one
CAS Number	77671-31-9
PubChem CID	53708
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₂H₁₂N₂O₂S
Molar mass	248.302 g/mol
3D model (JSmol)	Interactive image
SMILES CSc1ccc(cc1)C(=O)C2=C(C)NC(=O)N2